Asia Pacific Antibiotics Market to Reach US$ 15,784.01 million at a CAGR of 4.2% in 2027

The CephalosporinsSegment Held Largest Share of Asia Pacific Antibiotics Market in 2019

According to a new market research study of ‘Asia Pacific Antibiotics Marketto 2027 – Regional Analysis and Forecast by Drug Class and Action Mechanism,’the Asia Pacific antibiotics market is expected to reach US$ 15,784.01 millionby 2027 from US$ 11,591.97 million in 2019. The market is estimated to grow with a CAGR of 4.2% from 2020 to 2027. The report provides trends prevailing in the Asia Pacificantibiotics market and the factors driving market along with those that act as hindrances.

The antibiotics market, by drug class, is segmented into sulfonamides, aminoglycosides, carbapenem, macrolides, fluoroquinolones, penicillin, cephalosporin, and others. The cephalosporin segment held the largest share of the market in 2019, whereas the fluoroquinolones segment is anticipated to register the highest CAGR in the market during the forecast period. Cephalosporins have continued to serve as one of the largest class of antibiotics since their discovery in the 1950’s. These antibiotics are capable of treating infections that have mild life-threatening impact.

The Asia PacificAntibiotics marketis expected to grow owing to the prevalence of infectious diseases and consolidated government initiatives in emerging economies. However, tedious and expensive process of antibiotic development and the impact of COVID-19 pandemicare expected to restrain the growth of the market during the forecast years.

GlaxoSmithKline plc, Sanofi, Novartis AG, Astellas Pharma Inc,and Pfizer Incare some of the leading companies operating in the Asia Pacificantibiotics market.